Trevi Therapeutics
TRVI
13.14
-0.04
-0.30%
Trevi Therapeutics
US · TRVI
#2810 by market cap
Listed 2019
13.14
-0.04
-0.30%
Live - 5344 symbols - heartbeat 484s ago
· 2026-10-08 04:33
Pre-market
13.39
+1.90%
After-hours
13.14
0.00%
- Market cap
- 1.87B
- P/E (TTM)i
- -37.54
- P/Bi
- 5.82
- EPSi
- -0.32
- Div yieldi
- 0.00%
- 52W posi
- 35%
Reader sentiment
Are you bullish or bearish on TRVI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.3 percentage points.
Institutional ownership
- Held by institutions
- 106.25% -1.26pp
- Institutions
- 252 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund51.57%
VC/PE Fund29.77%
Hedge Fund18.94%
Public Company4.52%
Private Company0.87%
Individual/Insider0.70%
Government Pension Fund0.28%
Family Office/Trust0.18%
Insurance Company0.11%
Top holders as of 2026-06-30
New Enterprise Associates, Inc.
9.28% · 13.22M sh
FMR
8.82% · 12.56M sh
BlackRock
7.83% · 11.16M sh
Frazier Life Sciences Management, LP
6.98% · 9.94M sh
Vanguard Capital Management, LLC
4.47% · 6.37M sh
Wellington Management Group
3.99% · 5.68M sh
Vivo Capital, LLC
3.58% · 5.09M sh
Woodline Partners LP
2.86% · 4.08M sh
Vestal Point Capital, LP
2.18% · 3.10M sh
MPM BioImpact LLC
2.16% · 3.07M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| David Meeker | Independent Chairperson | 0.25% |
| Thomas Sciascia | Co-Founder & Chief Science Officer | 0.16% |
| Jennifer Good | Chief Executive Officer | 0.15% |
| Farrell Simon | Chief Commercial Officer | 0.06% |
| Lisa Delfini | Chief Financial Officer | 0.05% |
| Christopher Galletta | Controller & Chief Accounting Officer | 0.02% |
| Anne VanLent | Independent Director | 0.02% |
| Michael Heffernan | Lead Independent Director | 0.00% |
| New Enterprise Associates, Inc. | -- | -- |
| James Cassella | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Michael Heffernan | Lead Independent Director | Derivative Exercise and Sale | -39,473 | $3.04–15.88 |
| 2026-06-02 | Anne VanLent | Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | Dominick Colangelo | Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | Edward Mathers | Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | David Meeker | Independent Chairperson | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-06-02 | Michael Heffernan | Lead Independent Director | Other Derivative Acquisition | +35,000 | $13.45 |
| 2026-02-18 | James Cassella | Independent Director | Other Derivative Acquisition | +215,000 | $10.56 |
| 2026-02-18 | Jennifer Good | Chief Executive Officer | Other Derivative Acquisition | +675,000 | $10.56 |
| 2026-02-18 | Thomas Sciascia | Co-Founder & Chief Science Officer | Other Derivative Acquisition | +85,000 | $10.56 |
| 2026-02-18 | Christopher Galletta | Controller & Chief Accounting Officer | Other Derivative Acquisition | +35,000 | $10.56 |
| 2026-02-18 | Farrell Simon | Chief Commercial Officer | Other Derivative Acquisition | +160,000 | $10.56 |
| 2026-01-07 | David Hastings | Chief Financial Officer & Principal Financial Officer | Other Derivative Acquisition | +375,000 | $11.21 |
| 2025-12-01 | Christopher Galletta | Controller & Chief Accounting Officer | Derivative Exercise and Retained | +4,225 | $0.51 |
| 2025-10-06 | Lisa Delfini | Chief Financial Officer | Intent to Sell (Form 144) | -108,650 | $9.50 |
| 2025-10-02 | Lisa Delfini | Chief Financial Officer | Intent to Sell (Form 144) | -40,000 | $9.67 |
| 2025-08-26 | Lisa Delfini | Chief Financial Officer | Intent to Sell (Form 144) | -312,855 | $8.09 |
| 2025-06-10 | Anne VanLent | Independent Director | Other Derivative Acquisition | +45,000 | $6.25 |
| 2025-06-10 | Dominick Colangelo | Independent Director | Other Derivative Acquisition | +45,000 | $6.25 |
| 2025-06-10 | Edward Mathers | Independent Director | Other Derivative Acquisition | +45,000 | $6.25 |
| 2025-06-10 | David Meeker | Independent Chairperson | Other Derivative Acquisition | +45,000 | $6.25 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:33:25 · For reference only, not investment advice and not tailored to your situation.